COVID-19向け画像診断 (CT (コンピューター断層撮影)、X線、超音波）処置市場 (2020年～2024年)：2021年には820億米ドル以上の規模に到達

新型コロナウイルス感染症 (COVID-19) の感染拡大により、PCR検査用ロボットから綿棒や血清検査キットに至るまで、あらゆる検査機器や消耗品、試薬が払底するという深刻な事態が生じました。医療機器業界はこれまで経験したことのない危機に直面しています。

COVID-19感染拡大の緩和製品の市場規模 (2020年～2024年) のうち、検査関連の市場規模は全体の29～37%を占めると見込まれています。テストモダリティ（スタンドオフ温度測定、PCR、血清学的テストキットなど）の価格は年間10％～15％低下する一方、画像診断サービス（CT、超音波、X線検査など）の料金は年間5％～7％の速度で上昇する、と見込まれています。

当レポートでは、世界のCOVID-19向け画像診断処置の市場について分析し、全体的な市場規模 (処置件数) の動向見通しや、サブ市場別 - CT (コンピューター断層撮影)、X線画像、超音波画像 - の詳細動向、シナリオ別の将来予測、業界関係者が今後解決すべき課題、といった情報を取りまとめてお届けいたします。

当レポートの予測シナリオ

• 1. 楽観的シナリオ - ワクチンの大量摂取が2021年7月までに開始される場合
• 2. 慎重なシナリオ - 2025年まで集団予防接種が利用できない場合

A. 当レポートの主な問題意識・分析内容

• COVID-19向け画像診断処置 (CT、X線、超音波）の市場規模の予測値はどれだけか？ (2020年～2024年)
• 最も求心力の強いビジネスチャンスはどれか？
• 顧客がソリューションやサービスを購入する契機は何か？
• COVID-19画像診断処置（CT、X線、超音波）の市場動向はどうなっているのか？
• 3種類のサブ市場の今後の市場規模はどれだけか？ (2020年～2024年)
• 市場の浸透・成長に際しての課題とは何か？

B. 市場の部門別分析：分析フレームワークの詳細

• 1. 市場の促進・抑制要因
• 2. ビジネス機会
• 3. SWOT分析
• 4. 製品別・サービス別の競争力分析
  • 1. 市場参入障壁
  • 2. サプライヤーの交渉力
  • 3. バイヤーの交渉力
  • 4. 代替製品に対する障壁
• 5. 事業環境
• 6. 市場の動向見通し：サブ市場別 (全3種類、2020年～2024年)

The report includes the analysis of the following 3 COVID-19 related pharma sub-markets:

• 1. Computerized Tomography Market 2020-2024
• 2. X-Ray Procedures Market 2020-2024
• 3. Ultrasound Procedures Market 2020-2024

According to the report, the testing modalities, consumables and medical imaging services market in 2021 will be larger than $82 Billion.

The COVID-19 pandemic has led to acute deficiencies of essential testing products, consumables and reagents from robotic PCRs and COVID-19 PCR reagents to swabs and COVID-19 serologic tests kits. Never has the global leading healthcare communities been faced with the likelihood of having to ration testing or function without critical medical supplies and services on this magnitude.

According to the report, the cumulative 2020-2024 Testing market* share will be 29%-37% of the total COVID-19 pandemic mitigation products market. Testing modalities (e.g., Standoff Thermometry, PCR, Serologic Test Kits) prices will decline by 10%-15% per annum, while diagnostic imaging services (i.e. CT, Ultrasound and X-Ray procedures) prices will rise by 5%-7% per annum.

Testing and diagnosis for the presence and the clinical status of active infection provides critical information that is used to manage the COVID-19 response and home, ER and ICU treatment. There are five primary purposes for active infection testing:

• 1. Diagnostic Testing is used to confirm or support a clinical diagnosis of viral infection in symptomatic individuals and implement preventive measures to contain further

• 2. Testing for Contact Tracing is a process to trace, test and monitor persons that may have been in contact with infected individuals. This type of testing supports the identification and rapid isolation of new cases or those with presence of virus and no symptoms and helps to prevent further

• 3. Surveillance Testing is used to limit the spread of disease and enable public health authorities to assess and manage the risks associated with COVID-19, including testing asymptomatic individuals or wastewater testing. Objectives of surveillance include enabling rapid detection, isolation, testing and management of suspected cases and neighborhoods; guiding the implementation of control measures; detecting and containing outbreaks among exposed populations; and monitoring long-term epidemiological

• 4. Serologic Testing - serology (antibody) testing complements diagnostic testing (testing for active infection) by evaluating the prevalence of individuals in a community or country. who were previously infected by the virus. Currently, a positive antibody test does not indicate with certainty that an individual is immune to reinfection.

• 5. Diagnostic Imaging - diagnostic imaging procedures like chest X-ray, computerized tomography and cardiac / pulmonary ultrasound are used in ERs and ICUs to establish the state of COVID-19 patients.

The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen detection, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.

To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios:

• 1. Optimistic scenario - assumes (among other things) that mass vaccination will commence by July 2021

• 2. Conservative scenario - assumes (among other things) that no mass vaccination will be available until 2025

Why Buy this COVID-19 Diagnostic Imaging (Computerized Tomography, X-Ray, Ultrasound) Procedures Market - 2020-2024 Report?

A. Questions answered in this report include:

• What is the COVID-19 Diagnostic Imaging (Computerized Tomography, X-Ray, Ultrasound) Procedures Market size and what are the forecast trends during 2020-2024?

• What are the most attractive business opportunities?

• What drives the customers to purchase solutions and services?

• What are the COVID-19 Diagnostic Imaging (Computerized Tomography, X-Ray, Ultrasound) Procedures Market trends?

• What is the 3 sub-markets size over the 2020-2024 period?

• What are the challenges to market penetration & growth?

B. Detailed market analysis frameworks for each of the market sectors are provided, including:

• 1. Market drivers & inhibitors
• 2. Business opportunities
• 3. SWOT analysis
• 4. Competitive analysis for each of the products and services that covers:
  • 1. Barriers to Entry
  • 2. Supplier Power
  • 3. Buyer Power
  • 4. Barriers to Substitution.
• 5. Business environment
• 6. The 2020-2024 market segmented into 3submarkets